Aurobindo Pharma climbs after USFDA nod for OTC drug
The stock soared 2.31 per cent to Rs 738 on BSE. On NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
By PTI |
MUMBAI: Shares of Aurobindo Pharma ended higher by 3 per cent today after the firm got final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for treatment of osteoporosis.
The stock soared 2.31 per cent to Rs 738 on BSE.
On NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg," Aurobindo Pharma had said in a BSE filing on Saturday.
"The product is expected to be launched in Q1 of 2016-17," it had said.
The stock soared 2.31 per cent to Rs 738 on BSE.
On NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg," Aurobindo Pharma had said in a BSE filing on Saturday.
"The product is expected to be launched in Q1 of 2016-17," it had said.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsADVERTISEMENT
